TScan and Cellares Partner on Automated Cancer Therapy Manufacturing

TScan Therapeutics, a developer of cancer therapies, has partnered with Cellares to automate the production of its leading drug candidate, TSC-101. This treatment is currently in Phase I clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

The collaboration will focus on scaling up manufacturing for TSC-101, which targets a specific antigen on cancerous blood cells. By doing so, patients can receive infusions of healthy donor blood to support those at risk of relapse after a hematopoietic cell transplant.

Cellares's fully automated system and end-to-end Cell Shuttle platform will be used to evaluate large-scale production options. The quality control program, Cell Q, will assess the treatment's consistency and reliability.

TScan sees this partnership as essential for its upcoming pivotal study of TSC-101 in the coming quarter. By exploring automated manufacturing, it aims to build a stronger long-term production network and increase patient access to this potentially life-saving therapy.

The collaboration highlights the potential for allogeneic therapies based on healthy-donor material. However, developers must address practical questions about sourcing starting materials and ensuring their quality.